Johnson & Johnson kicks off giant study of single shot Covid-19 vaccine

Johnson & Johnson has begun dosing up to 60,000 volunteers in a study of its Covid-19 vaccine, marking the first big US trial of an inoculation that may work after just one shot.

J&J became the fourth vaccine maker to move its candidate into late-stage human studies in the US. If enrollment goes as expected, the trial could yield results as soon as year-end, allowing the company to seek emergency authorisation early next year, should it prove effective, according to Chief Scientific Officer Paul Stoffels.

“A single dose could be a very efficient tool to combat the pandemic as it is faster